Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more

Roivant Sciences surged 24% premarket after Pulmovant's Phase 2 mosliciguat trial showed a clinically meaningful, statistically significant reduction in pulmonary vascular resistance in pulmonary-hypertension patients with interstitial lung disease. Conversely, Novartis fell 12% after its Phase 3 del-desiran trial failed to show significant improvement in myotonic dystrophy type 1, while Peloton dropped more than 4% following a Morgan Stanley downgrade citing structural fitness-industry headwinds. Boston Scientific declined over 2% after warning that a cyberattack could affect its 2026 sales and profit targets; Lockheed Martin added 0.7% on a UBS upgrade to buy.

Analysis

ROIV’s move prices substantial probability of eventual commercial differentiation before the critical question is answered: whether the hemodynamic signal translates into exercise capacity, hospitalization, survival, and tolerability versus established inhaled vasodilator therapy. United Therapeutics (UTHR) is the incumbent read-through risk; a credible alternative could pressure its long-duration pulmonary-hypertension franchise, but the near-term clinical endpoint is insufficient to underwrite material share loss. Over the next 1-3 months, ROIV’s upside depends on full data disclosures—especially functional endpoints, oxygenation, discontinuations, and dose response—rather than the headline endpoint alone.

NVS’s failure raises the evidentiary bar across myotonic dystrophy type 1 programs, creating an initially negative sympathy read-through for Avidity Biosciences (RNA) and Dyne Therapeutics (DYN). The more nuanced implication is that delivery platform differentiation now matters more: a clean, reproducible biomarker-to-functional-benefit relationship from RNA or DYN would command a scarcity premium because a large-pharma comparator has failed. Until those datasets arrive, however, investors should assume higher regulatory and commercial-risk discounts for the entire DM1 category.

BSX faces a potentially more investable issue than a one-day cyber headline: if disruption affects ordering, case scheduling, field support, or inventory visibility, the earnings effect can extend beyond the remediation period through customer switching and delayed procedures. Medtronic (MDT), Abbott (ABT), and Edwards Lifesciences (EW) could capture incremental procedure volume where physician workflow is disrupted, though this requires evidence of channel-level impact before positioning. LMT’s analyst-driven strength is not a standalone catalyst; sustained outperformance needs backlog conversion, program-margin execution, and appropriations visibility rather than a multiple rerating on revised expectations alone.

Key Decisions for Investors

• Do not chase ROIV above the initial gap. Establish a watch position only after full Phase 2 data confirm functional benefit and acceptable oxygenation/safety; use UTHR as the hedge leg (long ROIV / short UTHR) only if the data support a credible competitive profile. Falsifier: no improvement in patient-relevant endpoints or clinically meaningful discontinuation rates.
• Buy a small basket of 3-6 month downside protection on RNA and DYN, or reduce existing DM1 exposure ahead of their next material clinical updates. The NVS outcome increases probability that DM1 efficacy hurdles are platform-wide; cover if either company reports a clear functional benefit alongside durable molecular correction.
• Set an earnings-revision alert on BSX: initiate a tactical short only if management quantifies a revenue or operating-margin impact, distributors flag fulfillment disruption, or consensus 2026 EPS falls by at least 3-5%. Pair against MDT or ABT to isolate execution risk; absent estimate cuts, the cyber event is likely insufficient for a durable short.
• Maintain LMT as a watch-list long rather than acting on the upgrade. Enter on confirmation of upward free-cash-flow guidance or incremental funded backlog; invalidate the thesis if program charges, fixed-price contract pressure, or delayed appropriations prevent conversion of demand into margins.